# Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder

> **NCT06969937** · PHASE2 · RECRUITING · sponsor: **Dr. med. Marcus Herdener** · enrollment: 75 (estimated)

## Conditions studied

- Alcohol Abuse/Dependence
- Alcohol Use Disorder (AUD)
- Alcoholism

## Interventions

- **DRUG:** Ketamine
- **BEHAVIORAL:** Real-time fMRI Neurofeedback Training
- **DRUG:** Placebo
- **BEHAVIORAL:** Sham Neurofeedback Training/ Ketamine

## Key facts

- **NCT ID:** NCT06969937
- **Lead sponsor:** Dr. med. Marcus Herdener
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06969937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06969937, "Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06969937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*